Targeting DNA Repair Defects Through PARP Inhibition in Prostate Cancer: Rationale, Evidence, and Clinical Implications
1.00 hr(s) | CME
Specialty: PARP Inhibitors
Therapeutic Area(s): Oncology
Release Date: July 22, 2020
Expiration Date: July 21, 2021
Location: Internet Activity Enduring
In this activity, Emmanuel S. Antonarakis, MD, discusses the rationale for targeting DNA repair defects through PARP inhibition and reviews recent safety and efficacy evidence with PARP inhibitors in patients with prostate cancer. He also highlights guidelines for genetic testing that is used to identify patients who might benefit from PARP inhibitor therapy and explores using PARP inhibitors in the urology clinic.